Class of Stock [Axis] Common Stock, $0.001 Par Value Per Share [Member] 8.625% Senior Notes Due 2026 [Member] Product and Service [Axis] Product Sales Net [Member] Other Revenues [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total Harrow Health, Inc. Stockholders' Equity [Member] Noncontrolling Interest [Member] Antidilutive Securities [Axis] Stock Options, Unvested RSUs and Warrants [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Legal Entity [Axis] Eton Pharmaceuticals, Inc. [Member] Statistical Measurement [Axis] Maximum [Member] Investment, Name [Axis] Melt Pharmaceuticals, Inc. [Member] Surface Ophthalmics, Inc. [Member] Investment Type [Axis] Loan [Member] Commissions [Member] Transfer Of Profit [Member] License [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Management Services Agreement [Member] Melt Loan Agreement [Member] Related Party [Axis] Investor [Member] Finite-Lived Intangible Assets by Major Class [Axis] Capitalized Internal Use Software [Member] Third Party Software License [Member] Capitalized Software Development Costs [Member] Minimum [Member] Patents [Member] Licenses [Member] Trademarks [Member] New Drug Applications [Member] Customer Relationships [Member] Trade Names [Member] Non-Competition Clause [Member] State Pharmacy Licenses [Member] Long-Term Debt, Type [Axis] Title of Individual [Axis] Scenario [Axis] Forecast [Member] Long-Lived Tangible Asset [Axis] Office and Laboratory Space [Member] Geographical [Axis] Carlsbad [Member] Ledgewood [Member] Lease Amendment [Member] Nashville [Member] Nashville 1 [Member] Mark L. Baum [Member] Options Held [Member] Andrew R. Boll [Member] John P. Saharek [Member] Director [Member] Plan Name [Axis] 2017 Incentive Stock and Awards Plan [Member] Stock Option Plan [Member] Employees and Consultant [Member] Unvested RSUs [Member] Subsidiary Stock [Member] Stock Option Plan [Member] Options Granted to Employees [Member] Exercise Price Range [Axis] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Range Five [Member] Range Six [Member] Range Seven [Member] Range Eight [Member] Range Nine [Member] Range Ten [Member] Class of Warrant or Right [Axis] Warrant [Member] Lender Warrants [Member] Employees [Member] Income Statement Location [Axis] Selling, General and Administrative Expenses [Member] Research and Development Expense [Member] Consultant [Member] Klarity License Agreement [Member] Richard L. Lindstrom, M.D [Member] Injectable Asset Purchase Agreement [Member] Dexycu Agreement [Member] Sales and Marketing Agreements [Member] Asset Purchase, License and Related Agreements [Member] Sintetica Agreement [Member] Due Within Thirty Days [Member] Wakamoto Agreement [Member] Presbyopia Asset Purchase Agreement [Member] Two Product Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Product Concentration Risk [Member] Cost of Goods and Service, Product and Service Benchmark [Member] Supplier Concentration Risk [Member] Supplier [Axis] Three Main Suppliers [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Investment in Eton Pharmaceuticals Accounts receivable, net Inventories Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Capitalized software development costs, net Operating lease right-of-use assets Intangible assets, net Investment in Melt Pharmaceuticals Goodwill TOTAL ASSETS Current liabilities Accounts payable and accrued expenses Accrued payroll and related liabilities Deferred revenue and customer deposits Current portion of operating lease obligations Current portion of finance lease obligations Total current liabilities Operating lease obligations, net of current portion Finance lease obligations, net of current portion Loans payable, net of unamortized debt discount TOTAL LIABILITIES Commitments and contingencies STOCKHOLDERS’ EQUITY Common stock, $0.001 par value, 50,000,000  shares authorized, 27,069,978 and 26,902,763 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated deficit TOTAL HARROW HEALTH STOCKHOLDERS’ EQUITY Noncontrolling interests TOTAL STOCKHOLDERS’ EQUITY TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Common stock, par value Common stock, sharess authorized Common stock, shares issued Common stock, shares outstanding Revenues: Total revenues Cost of sales Gross profit Operating expenses: Selling, general and administrative Research and development Total operating expenses Income from operations Other (expense) income: Interest expense, net Equity in losses of unconsolidated entities Investment loss from Eton Pharmaceuticals Loss on early extinguishment of debt Gain on forgiveness of PPP loan Other expense, net Total other expense, net Loss before income taxes Income taxes Net loss Preferred dividends and accretion of preferred stock issuance costs Net loss attributable to common stockholders Basic and diluted net loss per share of common stock Weighted average number of shares of common stock outstanding, basic and diluted Beginning balance, value Beginning Balance, shares Exercise of warrants Exercise of warrants, shares Exercise of employee stock options Exercise of employee stock options, shares Vesting of RSUs Vesting of RSUs, shares Shares withheld related to net share settlement of equity awards Shares withheld related to net share settlement of equity awards, shares Issuance of preferred shares, net of discount and issuance costs Issuance of preferred shares, net of discounts and issuance costs, shares Redemption of preferred shares Redemption of preferred shares, shares Payment of preferred dividends Stock-based compensation expense Net loss Ending balance, value Ending Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization Amortization of intangible assets Amortization of operating lease right-of-use assets Provision for bad debt expense Amortization of debt issuance costs and discount Gain on forgiveness of PPP loan Investment loss from investment in Eton Equity in losses of unconsolidated entities Loss on early extinguishment of loan Stock-based compensation Changes in assets and liabilities: Accounts receivable Inventories Prepaid expenses and other current assets Accounts payable and accrued expenses Accrued payroll and related liabilities Deferred revenue and customer deposits NET CASH PROVIDED BY OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES Net proceeds on sale of investments Investment in patent and trademark assets Purchases of property, plant and equipment NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Payments on finance lease obligations Net proceeds from 8.625% notes payable, net of costs Principal and exit fee payments on SWK loan Payment of taxes upon vesting of RSUs Proceeds from exercise of stock options Sale of preferred stock, net of discount and issuance costs Redemption of preferred stock Payment of preferred stock dividends NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash and cash equivalents Restricted cash CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for income taxes Cash paid for interest SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING Purchase of property, plant and equipment included in accounts payable and accrued expenses Right-of-use assets obtained in exchange for new operating lease obligations Accounting Policies [Abstract] DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue from Contract with Customer [Abstract] REVENUES Investments, Debt and Equity Securities [Abstract] INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS Investment In Surface Ophthalmics Inc. - Related Party Transactions INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS Inventory Disclosure [Abstract] INVENTORIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID EXPENSES AND OTHER CURRENT ASSETS Property, Plant and Equipment [Abstract] PROPERTY, PLANT AND EQUIPMENT Capitalized Software Development Costs CAPITALIZED SOFTWARE DEVELOPMENT COSTS Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS AND GOODWILL Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Debt Disclosure [Abstract] DEBT Leases LEASES Equity [Abstract] STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Risks and Uncertainties [Abstract] CONCENTRATIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Risks, Uncertainties and Liquidity Segments Basic and Diluted Net Loss per Common Share Investment in Eton Pharmaceuticals, Inc Investment in Melt Pharmaceuticals, Inc. – Related Party Investment in Surface Ophthalmics, Inc. – Related Party Impairment of Equity Method Investments and Note Receivable SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE SCHEDULE OF INVESTMENT SCHEDULE OF DISAGGREGATED REVENUE SCHEDULE OF CONDENSED INCOME STATEMENT SCHEDULE OF CONDENSED BALANCE SHEET SUMMARY OF CONDENSED INCOME STATEMENT SUMMARY OF CONDENSED BALANCE SHEET SCHEDULE OF INVENTORIES SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS SCHEDULE OF INTANGIBLE ASSETS SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES SUMMARY OF FUTURE MINIMUM PAYMENTS SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES SCHEDULE OF STOCK OPTION PLAN ACTIVITY SCHEDULE OF FAIR VALUE ASSUMPTIONS SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS Numerator – net loss attributable to common stockholders Denominator – weighted average number of shares outstanding, basic and diluted Net loss per share of common stock, basic and diluted Investment Income [Table] Net Investment Income [Line Items] Cost Basis Share of Equity Method Losses Paid in Kind Interest In Substance Capital Contributions Net carrying value Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Antidilutive securities Number of shares vestted, RSUs Number of shares owned Ownership percentage Shares price Unrealized Gain (Loss) on Investments Investment owned, at fair value Reduction in common stock investment Investment interest rate Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Contract with Customer, Liability, Current Revenues, net Loss from operations Current assets Non-current assets Total assets Total liabilities Total preferred stock and stockholders’ deficit Total liabilities and stockholders’ equity Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Administrative fees expense Reimbursable expenses Due from Related Parties Loan amount Debt Instrument, Interest Rate, Stated Percentage Increase in interest rate Accounts receivable transferred to note receivable Investment Owned, Balance, Shares Raw materials Work in progress Finished goods Total inventories Prepaid insurance Due from Melt Pharmaceuticals Other prepaid expenses Deposits and other current assets Total prepaid expenses and other current assets Computer hardware Furniture and equipment Lab and pharmacy equipment Leasehold improvements Property, plant and equipment, gross Accumulated depreciation Property, plant and equipment, net Depreciation Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Total gross capitalized software for internal-use Accumulated amortization Capitalized internal-use software in process Total finite lived intangible assets net Amortization expense Finite-Lived Intangible Asset, Useful Life Cost Accumulated amortization Impairment Net Carrying value Finite-Lived Intangible Assets, Amortization Method Remainder of 2022 2023 2024 2025 2026 Thereafter Intangible assets Accounts payable Other accrued expenses Accrued interest Total accounts payable and accrued expenses Remainder of 2022 2023 2024 2025 2026 Total minimum payments Less: amount representing interest payments Notes payable, gross Less: unamortized discount, net of premium Notes payable, net of unamortized discount Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Debt Instrument, Face Amount Debt Instrument, Increase (Decrease), Net Shares Issued, Price Per Share Proceeds from Issuance of Debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Interest Expense, Debt Debt Issuance Costs, Net Debt Instrument, Unamortized Premium Debt Instrument, Interest Rate During Period Debt Instrument, Redemption, Description Interest Expense, Other Long-Term Debt Amortization of Debt Issuance Costs and Discounts Schedule Of Future Lease Payment Under Operating Leases Remainder of 2022 2023 2024 2025 2026 Thereafter Total minimum lease payments Less: amount representing interest payments Total operating lease liabilities Less: current portion, operating lease liabilities Operating lease liabilities, net of current portion Lease term Area of Land Lease expiration date description Additional square footage Lessee, Operating Lease, Option to Extend Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Payments Operating Lease, Expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of shares, outstanding, beginning balance Weighted average exercise price, outstanding, beginning balance Number of shares, options granted Weighted average exercise price, options granted Number of shares, options exercised Weighted average exercise price, options exercised Number of shares, options cancelled/forfeited Weighted average exercise price, options cancelled/forfeited Number of shares, outstanding, ending balance Weighted average exercise price, outstanding, ending balance Weighted average. remaining contractual life, options outstanding Aggregate intrinsic value, options outstanding Number of shares, options exercisable Weighted average exercise price, options exercisable Weighted average. remaining contractual life, options exercisable Aggregate intrinsic value, options exercisable Number of shares, options vested and expected to vest Weighted average exercise price, options vested and expected to vest Weighted average. remaining contractual life, options vested and expected to vest Aggregate intrinsic value, options vested and expected to vest Weighted-average fair value of options granted Expected terms (in years) Expected volatility Risk-free interest rate Dividend yield Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Range of Exercise Prices, minimum Range of Exercise Prices, maximum Number of Options Outstanding Weighted Average Remaining Contractual Life in Years Weighted Average Exercise Price Number Exercisable Weighted Average Exercisable Exercise Price Number of RSUs unvested, outstanding, beginning balance Weighted average grant date fair value, beginning balance Number of RSUs granted Weighted average grant date fair value, RSUs granted Number of RSUs vested Weighted average grant date fair value, RSUs vested Number of RSUs cancelled/forfeited Weighted average grant date fair value, RSUs cancelled/forfeited Number of RSUs unvested, outstanding, ending balance Weighted average grant date fair value, ending balance Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Number of Shares Warrants Outstanding, beginning balance Weighted average. exercise price, outstanding, beginning balance Number of shares warrants outstanding, granted Share-based payment award, non-option equity instruments, exercised Share-based payment award, non - option equity instruments, expirations Number of shares warrants outstanding, ending balance Weighted average. exercise price, outstanding, ending balance Weighted average remaining contractual life of the outstanding warrants in years Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Issue Date Warrants Outstanding Exercise Price Expiration Date Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Total Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Preferred stock, shares authorized Preferred stock, par or stated value per share Preferred stock, shares issued Preferred stock, shares outstanding Number of shares isssued Cashless exercise of options, shares Cashless exercise of options, price per shares Common stock withheld on cashless exercise Common stock withheld for payroll tax withholdings, shares Common stock withheld for payroll tax withholdings, value Proceeds from issuance of common stock Exercise Price Number of restricted stock units granted Common stock withheld for payroll tax withholdings, value Number of restricted stock units granted Share-based compensation arrangement by share-based payment award, number of shares authorized Share-based compensation arrangement by share-based payment award, number of shares available for grant Closing price of common stock price per share Weighted avg. remaining contractual life, options exercisable Share-based compensation arrangement by share-based payment award, plan modification, description and terms Unrecognized compensation expense related to unvested stock options granted under the plan Expense expected to recognize over the weighted-average remaining vesting period Intrinsic value of options exercised Loss Contingencies [Table] Loss Contingencies [Line Items] Royalty payment description Milestone payment in cash Royalty expense Initial milestone payment Expiration date Commission revenues Description for commission payments Commission payments percentage Commission expenses Payment for royalties Commercial payments for royalties Milestone payment in cash Concentration Risk [Table] Concentration Risk [Line Items] Concentration risk percentage 8.625% Senior Notes Due 2026 [Member] Common Stock, $0.001 Par Value Per Share [Member] Investments and other noncurrent assets one. Equity in losses of unconsolidated entities. Gain loss on forgiveness of debt. Total Harrow Health, Inc. Stockholders' Equity [Member] Stock issued during period for exercise of warrants. Issuance of preferred shares. Stock issued during period shares for exercise of warrants. Stock Issued Of Preferred Shares During Period. Reconciliation Of Cash Cash Equivalents And Restriced Cash At End Of Period Abstract. Cash Cash Equivalents And Restricted Cash At End Of Period. Losses on extinguishment of debt. Payment Of Taxes For Vesting Of Restricted Stock Unit. Proceeds From Sale Of Preferred Stock Net Of Discount And Issuance Costs. Payments For Redemption Of Preferred Stock. Purchase of property, plant and equipment included in accounts payable and accrued expenses. Risks Uncertainties And Liquidity [Policy Text Block] Investment One [Policy Text Block] Investment Two [Policy Text Block] Stock Options, Unvested RSUs and Warrants [Member]. Eton Pharmaceuticals, Inc. [Member] Melt Pharmaceuticals Inc [Member] Reduction in common stock investment. Investment paid in kind interest. Loan [Member] Surface Ophthalmics, Inc. [Member] Management Services Agreement [Member] Schedule of Condensed Income Statement One [Table Text Block] Schedule of Condensed Balance Sheet One [Table Text Block] Melt Loan Agreement [Member] Accounts receivable transferred to note receivable. Investments And Agreements Related Party Transactions [Text Block] Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block] Computer hardware gross. Capitalized Software Development Costs [Text Block] Capitalized Software Development Costs [Table Text Block] Capitalized Computer Software Internal Use In Process Capitalized Software Development Costs [Member] Licenses [Member] New Drug Applications [Member] Non-Competition Clause [Member] State Pharmacy Licenses [Member] Finite lived intangible assets impairment. Finite Lived Intangible Assets Amortization Expense After Year Four Lessee Operating Lease And Finance Lease [Text Block] Office and Laboratory Space [Member] Carlsbad [Member] Lease expiration date description. Ledgewood [Member] Additional area of land. Lease Amendment [Member] Nashville [Member] Nashville 1 [Member] Lessee Operating Lease Liability Payments Due After Year Four. Mark L. Baum [Member] Cashless exercise of options shares. Cashless exercise of options price per shares. Common stock withheld on cashless exercise. Common stock withheld for payroll tax withholdings, shares. Common stock withheld for payroll tax withholdings, value. Andrew R. Boll [Member] Common stock withheld for payroll tax withholdings, value. John P. Saharek [Member] 2017 Incentive Stock and Awards Plan [Member] Stock Option Plan [Member] Closing price of common stock price per share. Stock Option Plan [Member] Employees and Consultant [Member] Options Granted to Employees [Member] Range One [Member] Range Two [Member] Range Three [Member] Range Five [Member] Range Six [Member] Range Eight [Member] Range Nine [Member] Range Ten [Member] Range Four [Member] Range Seven [Member] Unvested RSUs [Member] Schedule of Warrants Outstanding [Table Text Block] Subsidiary Stock [Member] Warrants issuance date. Lender Warrants [Member] Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format. Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term. Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price. Royalty payment description. Klarity License Agreement [Member] Richard L. Lindstrom, M.D [Member] Milestone payment in cash. Injectable Asset Purchase Agreement [Member] Initial milestone payment. Commission expiration date. Dexycu Agreement [Member] Commission revenues Description for commission payments. Sales and Marketing Agreements [Member] Commission payments, percentage. Asset Purchase, License and Related Agreements [Member] Sintetica Agreement [Member] Due Within Thirty Days [Member] Wakamoto Agreement [Member] Presbyopia Asset Purchase Agreement [Member] Milestone payments on payables. Two Product Concentration Risk [Member] Three Main Suppliers [Member] Commercial payments for royalties. Stock Option Plan [Member] [Default Label] Assets, Current Liabilities, Current Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Cost of Goods and Services Sold Gross Profit Operating Expenses Interest Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Preferred Stock Dividends and Other Adjustments Shares, Outstanding Stock Issued During Period, Shares, Other Stock Redeemed or Called During Period, Value Stock Redeemed or Called During Period, Shares Payments of Ordinary Dividends, Preferred Stock and Preference Stock Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Employee Related Liabilities Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities Payments to Acquire Intangible Assets Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Repayments of Notes Payable PaymentOfTaxesForVestingOfRestrictedStockUnit PaymentsForRedemptionOfPreferredStock Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash and Cash Equivalents, at Carrying Value Restricted Cash CashCashEquivalentsAndRestrictedCashAtEndOfPeriod Equity Method Investment, Aggregate Cost Investment Company, Committed Capital Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Capitalized Computer Software, Accumulated Amortization Finite-Lived Intangible Assets, Net Accounts Payable and Accrued Liabilities Long-Term Debt, Maturity, Remainder of Fiscal Year Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Long-Term Debt Interest Payable, Current Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Weighted Avg. Exercise Price, Outstanding, beginning balance Class of Warrant or Right, Number of Securities Called by Warrants or Rights CommonStockWithheldForPayrollTaxWithholdingsValue MilestonePaymentsOnPayables